Expression Of Ki-67 And Its Relationship With Response To Chemotherapy And Prognosis In Human Breast Cancer

[Objective]:To investigate the expression of Ki-67 and its relationship with response to chemotherapy and prognosis, and to explore whether ki-67 can be used as a predictor for chemosensitivity and for prognosis in human breast cancer.[Methods]:Collected 64 cases of breast cancer patients who underwent neoadjuvant chemotherapy or first line palliative chemotherapy from January 2005 to July 2010 in the affiliated tumor hospital of Guangxi Medical University, including 14 cases ofⅡa ~Ⅲb neoadjuvant patients and 50 with stageⅣrecurrence, metastatic patients. The expression of Ki-67 was detected by the Immunohistochemical technology in this 64 breast cancer specimens. Analyze its correlations with clinicopathological factors and response to chemotherapy and prognosis.[Results]: The positive expression rate of Ki-67 was 54.69% in the object. No correlations were found between expression of Ki-67 and age, menstruation, axillary lymph node metastasis, histological type and ER, PR C-erbB-2 level. In this study of 64 patients, the chemotherapy effective rate (RR) of the Ki-67 positive group was 34.3%, compared to 37.9% in the Ki-67 negative group. No statistically significant was found. In the Ki-67 high expression group and low expression group also, no statistically significant was found (36.0%vs.35.9%). With the expression of Ki-67 levels increasing(-～+++), chemotherapy effective rate has no significant statistical differences(P=0.649). In the Ki-67/ER, Ki-67/PR and Ki-67/C-erbB-2 subgroups, no significant differences were found between each subgroup (P>0.05). In addition, neither in the anthracycline-based chemotherapy group and non-anthracycline-based chemotherapy group, or taxane-based chemotherapy group and non-taxane-based chemotherapy group, there was no significant difference between Ki-67 and its correlation to chemotherapy effective rate (P value > 0.05). In the Long-term survival of the 50 recurrence, metastatic patients, the Ki-67 negative group and the low expression group show no survival advantage. 1, 2 and 3-year OS rate was not higher than the positive and the high expression group. The differences were not statistically significant (P> 0.05).[Conclusions]: In breast cancer, there was no significant correlation between the Ki-67 and age, menstruation, axillary lymph node metastasis, histological type or ER, PR and C-erbB-2 level. There were no significant correlations between Ki-67 and the effectiveness of chemotherapy and prognosis. Ki-67 may not be used as a predictor for chemosensitivity and for prognosis in human breast cancer.